Brief: Epigenomics: Liquid Biopsy Test For Liver Cancer Detection To Obtain CE Mark
02/07/2018 06:41
July 2 (Reuters) - EPIGENOMICS AG ECXn.DE :
* LIQUID BIOPSY TEST FOR LIVER CANCER DETECTION TO OBTAIN CE
MARK
* PLANS TO CE MARK MSEPT9 BLOOD TEST FOR LIVER CANCER BY
YEAR-END
2018, ENABLING COMMERCIALIZATION IN EUROPE
* PROSPECTIVE U.S. TRIAL FOR FDA SUBMISSION TO BE INITIATED
IN
2019
* INVESTIGATING OPTIMAL PATH FOR CFDA APPROVAL IN CHINA
Source text for Eikon: ID:nEQRb8mta
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns